Skip to Content

Bayer AG

BAYN: XETR (DEU)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
€75.00VhbhhcmBqp

Bayer’s Core Business Lines in Healthcare and Crop Sciences Look Well Positioned Over the Long Term

Business Strategy and Outlook

Largely on the basis of the strong competitive advantages of the healthcare group and to a lesser extent the crop science business, we believe Bayer has created a wide economic moat. Also, the past divestiture of no-moat material science group Covestro leaves the company in a stronger competitive position.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of BAYN so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center